HTF Market Intelligence released a new research report of 128 pages on title ‘Endometriosis – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies.
Endometriosis – Pipeline Review, H1 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis – Pipeline Review, H1 2017, provides an overview of the Endometriosis (Women’s Health) pipeline landscape.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. The predisposing factors uterine abnormalities, History of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
Request a sample report @ https://www.htfmarketreport.com/sample-report/398210-endometriosis-pipeline-review
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Endometriosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometriosis (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 6, 1, 17, 7 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.
Endometriosis (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women’s Health).
– The pipeline guide reviews pipeline therapeutics for Endometriosis (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Endometriosis (Women’s Health) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Endometriosis (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women’s Health)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women’s Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Endometriosis (Women’s Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Addex Therapeutics Ltd
APAvadis Biotechnologies Srl
Astellas Pharma Inc
Dongkook Pharmaceutical Co Ltd
Enteris BioPharma Inc
Forendo Pharma Ltd
Kissei Pharmaceutical Co Ltd
Lipicard Technologies Ltd
Luye Pharma Group Ltd
Nippon Shinyaku Co Ltd
Orphagen Pharmaceuticals Inc
Repros Therapeutics Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Company Ltd
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/398210-endometriosis-pipeline-review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Global Markets Direct Report Coverage 6
Endometriosis – Overview 7
Endometriosis – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Endometriosis – Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Endometriosis – Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Addex Therapeutics Ltd 28
APAvadis Biotechnologies Srl 28
Astellas Pharma Inc 29
Bayer AG 29
Dongkook Pharmaceutical Co Ltd 30
ElexoPharm GmbH 30
EndoCeutics Inc 31
Enteris BioPharma Inc 31
Evotec AG 32
Forendo Pharma Ltd 32
Kissei Pharmaceutical Co Ltd 33
Lipicard Technologies Ltd 33
Luye Pharma Group Ltd 34
Nippon Shinyaku Co Ltd 34
Ogeda SA 35
Orphagen Pharmaceuticals Inc 35
Philogen SpA 36
Repros Therapeutics Inc 36
SK Chemicals Co Ltd 37
Takeda Pharmaceutical Company Ltd 37
ValiRx Plc 38
Viramal Ltd 38
Endometriosis – Drug Profiles 39
acolbifene hydrochloride + GnRH Agonist + prasterone – Drug Profile 39
ADX-68692 – Drug Profile 40
ASP-1707 – Drug Profile 41
BAY-1128688 – Drug Profile 42
BAY-1158061 – Drug Profile 43
danazol – Drug Profile 44
Drug 1 for Endometriosis – Drug Profile 45
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/398210-endometriosis-pipeline-review
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=398210
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218